Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Prostate Cancer

Free Subscription Articles published in Cancer Retrieve available abstracts of 80 articles: HTML format Text format

Single Articles

January 2019
1. SONPAVDE G, Agarwal N, Pond GR, Nagy RJ, et al
   Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
   Cancer. 2019 Jan 8. doi: 10.1002/cncr.31959.
   PubMed     Text format     Abstract available
   
   
   
2. PRINTZ C
   Early-age drinkers more likely to have high-grade prostate cancer later.
   Cancer. 2019;125:11.
   PubMed     Text format    
   
   
   December 2018
3. HOGE C, George A, Sidana A
   Partial gland therapy for prostate cancer.
   Cancer. 2018 Dec 20. doi: 10.1002/cncr.31823.
   PubMed     Text format    
   
   
   
4. KING MT, Nguyen PL, D'Amico AV, Orio PF 3rd, et al
   Reply to Partial gland therapy for prostate cancer.
   Cancer. 2018 Dec 20. doi: 10.1002/cncr.31822.
   PubMed     Text format    
   
   
   
5. WHITE C, Nimeh T, Gazelle GS, Weinstein MC, et al
   A decision analysis comparing 3 active surveillance protocols for the treatment of patients with low-risk prostate cancer.
   Cancer. 2018 Dec 18. doi: 10.1002/cncr.31884.
   PubMed     Text format     Abstract available
   
   
   
6. FOSTER CC, Weichselbaum RR, Pitroda SP
   Oligometastatic prostate cancer: Reality or figment of imagination.
   Cancer. 2018 Dec 6. doi: 10.1002/cncr.31860.
   PubMed     Text format     Abstract available
   
   
   
7. LI T, Franco-Villalobos C, Proskorovsky I, Sorensen SV, et al
   Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: Results from LATITUDE.
   Cancer. 2018 Dec 6. doi: 10.1002/cncr.31847.
   PubMed     Text format     Abstract available
   
   
   
8. SMITH L, Ae Lee J, Mun J, Pakpahan R, et al
   Levels and patterns of self-reported and objectively-measured free-living physical activity among prostate cancer survivors: A prospective cohort study.
   Cancer. 2018 Dec 5. doi: 10.1002/cncr.31857.
   PubMed     Text format     Abstract available
   
   
   
9. SENEVIRATNE MG, Bozkurt S, Patel MI, Seto T, et al
   Distribution of global health measures from routinely collected PROMIS surveys in patients with breast cancer or prostate cancer.
   Cancer. 2018 Dec 4. doi: 10.1002/cncr.31895.
   PubMed     Text format     Abstract available
   
   
   November 2018
10. BORNO HT, Lichtensztajn DY, Gomez SL, Palmer NR, et al
    Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer.
    Cancer. 2018 Nov 16. doi: 10.1002/cncr.31826.
    PubMed     Text format     Abstract available
    
    
    
11. NEGOITA S, Mariotto A, Benard V, Kohler BA, et al
    Reply to Annual Report to the Nation on the Status of Cancer, Part II: Recent changes in prostate cancer trends and disease characteristics.
    Cancer. 2018 Nov 14. doi: 10.1002/cncr.31845.
    PubMed     Text format    
    
    
    
12. MCKAY RR, Werner L, Jacobus SJ, Jones A, et al
    A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer.
    Cancer. 2018 Nov 14. doi: 10.1002/cncr.31836.
    PubMed     Text format     Abstract available
    
    
    
13. CURRY SJ, Krist AH, Owens DK
    Annual Report to the Nation on the Status of Cancer, Part II: Recent changes in prostate cancer trends and disease characteristics.
    Cancer. 2018 Nov 14. doi: 10.1002/cncr.31846.
    PubMed     Text format    
    
    
    
14. SUNDI D, Tosoian JJ, Nyame YA, Alam R, et al
    Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers.
    Cancer. 2018 Nov 13. doi: 10.1002/cncr.31833.
    PubMed     Text format     Abstract available
    
    
    
15. RESNICK MJ, Graves AJ, Gambrel RJ, Thapa S, et al
    The association between medicare accountable care organization enrollment and breast, colorectal, and prostate cancer screening.
    Cancer. 2018 Nov 9. doi: 10.1002/cncr.31700.
    PubMed     Text format     Abstract available
    
    
    October 2018
16. PRINTZ C
    New drug option for men with aggressive prostate cancer.
    Cancer. 2018;124:3797.
    PubMed     Text format    
    
    
    September 2018
17. JANG TL, Patel N, Faiena I, Radadia KD, et al
    Comparative Effectiveness of Radical Prostatectomy With Adjuvant Radiotherapy Versus Radiotherapy Plus Androgen Deprivation Therapy for Men With Advanced Prostate Cancer.
    Cancer. 2018 Sep 25. doi: 10.1002/cncr.31726.
    PubMed     Text format     Abstract available
    
    
    
18. SKOLARUS TA, Caram ME, Chapman CH, Smith DC, et al
    Castration Remains Despite Decreasing Definitive Treatment of Localized Prostate Cancer in the Elderly: A Case for De-Implementation.
    Cancer. 2018 Sep 7. doi: 10.1002/cncr.31665.
    PubMed     Text format    
    
    
    July 2018
19. ALONGI F, Corradini S, Arcangeli S
    Radiation therapy does not increase survival in addition to standard androgen deprivation therapy for metastatic prostate cancer: An old, faded picture?
    Cancer. 2018 Jul 5. doi: 10.1002/cncr.31626.
    PubMed     Text format    
    
    
    
20. DALL'ERA MA, Lo MJ, Chen JY, Cress R, et al
    Reply to Radiation therapy does not increase survival in addition to standard androgen deprivation therapy for metastatic prostate cancer: An old, faded picture?
    Cancer. 2018 Jul 5. doi: 10.1002/cncr.31625.
    PubMed     Text format    
    
    
    
21. KING MT, Nguyen PL, Boldbaatar N, Tempany CM, et al
    Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer.
    Cancer. 2018 Jul 5. doi: 10.1002/cncr.31568.
    PubMed     Text format     Abstract available
    
    
    June 2018
22. PRINTZ C
    Combined therapies improve survival in aggressive prostate cancer.
    Cancer. 2018;124:2470.
    PubMed     Text format    
    
    
    
23. MODI PK, Kaufman SR, Borza T, Yan P, et al
    Variation in prostate cancer treatment and spending among Medicare shared savings program accountable care organizations.
    Cancer. 2018 Jun 15. doi: 10.1002/cncr.31573.
    PubMed     Text format     Abstract available
    
    
    May 2018
24. NEGOITA S, Feuer EJ, Mariotto A, Cronin KA, et al
    Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics.
    Cancer. 2018 May 22. doi: 10.1002/cncr.31549.
    PubMed     Text format     Abstract available
    
    
    
25. THOMPSON IM JR
    The pendulum swings back: Screening for prostate cancer in 2018.
    Cancer. 2018 May 22. doi: 10.1002/cncr.31555.
    PubMed     Text format    
    
    
    
26. KEARNS JT, Holt SK, Wright JL, Lin DW, et al
    PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
    Cancer. 2018 May 21. doi: 10.1002/cncr.31337.
    PubMed     Text format     Abstract available
    
    
    
27. FILSON CP
    Moving toward a more rational, evidence-based approach to PSA screening, diagnosis, and treatment of prostate cancer.
    Cancer. 2018 May 21. doi: 10.1002/cncr.31332.
    PubMed     Text format    
    
    
    
28. BRYANT AK, D'Amico AV, Nguyen PL, Einck JP, et al
    Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.
    Cancer. 2018 May 4. doi: 10.1002/cncr.31400.
    PubMed     Text format     Abstract available
    
    
    
29. BRAWLEY OW
    Prostate cancer screening: And the pendulum swings.
    Cancer. 2018 May 3. doi: 10.1002/cncr.31380.
    PubMed     Text format    
    
    
    
30. HELGSTRAND JT, Roder MA, Klemann N, Toft BG, et al
    Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
    Cancer. 2018 May 3. doi: 10.1002/cncr.31384.
    PubMed     Text format     Abstract available
    
    
    April 2018
31. ZHEN JT, Syed J, Nguyen KA, Leapman MS, et al
    Genetic testing for hereditary prostate cancer: Current status and limitations.
    Cancer. 2018 Apr 18. doi: 10.1002/cncr.31316.
    PubMed     Text format     Abstract available
    
    
    
32. REEVE BB, Tan X, Chen RC, Usinger DS, et al
    Symptom and function profiles of men with localized prostate cancer.
    Cancer. 2018 Apr 16. doi: 10.1002/cncr.31401.
    PubMed     Text format     Abstract available
    
    
    March 2018
33. GOLAN R, Bernstein AN, Gu X, Dinerman BA, et al
    Increased resource use in men with metastatic prostate cancer does not result in improved survival or quality of care at the end of life.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31297.
    PubMed     Text format     Abstract available
    
    
    
34. DALL'ERA MA, Lo MJ, Chen J, Cress R, et al
    Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer.
    Cancer. 2018 Mar 2. doi: 10.1002/cncr.31285.
    PubMed     Text format     Abstract available
    
    
    January 2018
35. KAUR D, Ulloa-Perez E, Gulati R, Etzioni R, et al
    Racial disparities in prostate cancer survival in a screened population: Reality versus artifact.
    Cancer. 2018 Jan 25. doi: 10.1002/cncr.31253.
    PubMed     Text format     Abstract available
    
    
    
36. MCHUGH DJ, Root JC, Nelson CJ, Morris MJ, et al
    Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire?
    Cancer. 2018 Jan 16. doi: 10.1002/cncr.31153.
    PubMed     Text format     Abstract available
    
    
    
37. MCDUFF SGR, Chen MH, Renshaw AA, Loffredo MJ, et al
    Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer.
    Cancer. 2018 Jan 16. doi: 10.1002/cncr.31217.
    PubMed     Text format     Abstract available
    
    
    
38. PRINTZ C
    Evolving detection and treatment methods change approaches to prostate cancer: US Preventive Services Task Force draft recommendations now align more closely with others.
    Cancer. 2018;124:11-12.
    PubMed     Text format    
    
    
    December 2017
39. ATKINS KM, Chen MH, Wu J, Renshaw AA, et al
    Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.
    Cancer. 2017 Dec 20. doi: 10.1002/cncr.31204.
    PubMed     Text format     Abstract available
    
    
    
40. SAILER V, Schiffman MH, Kossai M, Cyrta J, et al
    Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.
    Cancer. 2017 Dec 19. doi: 10.1002/cncr.31173.
    PubMed     Text format     Abstract available
    
    
    
41. PAL SK, Patel J, He M, Foulk B, et al
    Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).
    Cancer. 2017 Dec 19. doi: 10.1002/cncr.31161.
    PubMed     Text format     Abstract available
    
    
    
42. STEELE CB, Li J, Huang B, Weir HK, et al
    Prostate cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.
    Cancer. 2017;123 Suppl 24:5160-5177.
    PubMed     Text format     Abstract available
    
    
    
43. DE CARVALHO TM, Heijnsdijk EAM, de Koning HJ
    Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance.
    Cancer. 2017 Dec 12. doi: 10.1002/cncr.31141.
    PubMed     Text format     Abstract available
    
    
    
44. ALBERTSEN PC
    Prostate cancer screening with prostate-specific antigen: Where are we going?
    Cancer. 2017 Dec 12. doi: 10.1002/cncr.31140.
    PubMed     Text format    
    
    
    
45. MAHAL BA, Chen YW, Sethi RV, Padilla OA, et al
    Travel distance and stereotactic body radiotherapy for localized prostate cancer.
    Cancer. 2017 Dec 12. doi: 10.1002/cncr.31190.
    PubMed     Text format     Abstract available
    
    
    
46. ALIBHAI SMH, Breunis H, Timilshina N, Hamidi MS, et al
    Improving bone health in men with prostate cancer receiving androgen deprivation therapy: Results of a randomized phase 2 trial.
    Cancer. 2017 Dec 6. doi: 10.1002/cncr.31171.
    PubMed     Text format     Abstract available
    
    
    November 2017
47. ALBISINNI S, Joniau S, Quackels T, De Coster G, et al
    Current trends in patient enrollment for robotic-assisted laparoscopic prostatectomy in Belgium.
    Cancer. 2017;123:4139-4146.
    PubMed     Text format     Abstract available
    
    
    
48. FREEDLAND SJ, Vidal AC, Howard LE, Terris MK, et al
    Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.
    Cancer. 2017;123:4199-4206.
    PubMed     Text format     Abstract available
    
    
    October 2017
49. MAHAL AR, Mahal BA, Nguyen PL, Yu JB, et al
    Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance.
    Cancer. 2017 Oct 30. doi: 10.1002/cncr.31106.
    PubMed     Text format     Abstract available
    
    
    
50. GONZALEZ BD, Small BJ, Cases MG, Williams NL, et al
    Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia.
    Cancer. 2017 Oct 26. doi: 10.1002/cncr.31024.
    PubMed     Text format     Abstract available
    
    
    
51. BORZA T, Kaufman SR, Yan P, Herrel LA, et al
    Early effect of Medicare Shared Savings Program accountable care organization participation on prostate cancer care.
    Cancer. 2017 Oct 20. doi: 10.1002/cncr.31081.
    PubMed     Text format     Abstract available
    
    
    
52. CHAD-FRIEDMAN E, Coleman S, Traeger LN, Pirl WF, et al
    Psychological distress associated with cancer screening: A systematic review.
    Cancer. 2017;123:3882-3894.
    PubMed     Text format     Abstract available
    
    
    
53. CAMPODONICO F, Grillo-Ruggeri F, Grimaldi A, Zanardi S, et al
    Prostate cancer multidisciplinary clinic and decisional regret: Looking for a longer follow-up.
    Cancer. 2017 Oct 4. doi: 10.1002/cncr.31054.
    PubMed     Text format    
    
    
    
54. HURWITZ LM, Cullen J
    Reply to Prostate cancer multidisciplinary clinic and decisional regret: Looking for a longer follow-up.
    Cancer. 2017 Oct 4. doi: 10.1002/cncr.31053.
    PubMed     Text format    
    
    
    September 2017
55. LOPPENBERG B, Friedlander DF, Krasnova A, Tam A, et al
    Variation in the use of active surveillance for low-risk prostate cancer.
    Cancer. 2017 Sep 13. doi: 10.1002/cncr.30983.
    PubMed     Text format     Abstract available
    
    
    August 2017
56. YANG DD, Mahal BA, Muralidhar V, Boldbaatar N, et al
    Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer.
    Cancer. 2017 Aug 22. doi: 10.1002/cncr.30948.
    PubMed     Text format     Abstract available
    
    
    
57. HOFFMAN RM, Volk RJ, Wolf AMD
    Making the grade: The newest US Preventive Services Task Force prostate cancer screening recommendation.
    Cancer. 2017 Aug 22. doi: 10.1002/cncr.30941.
    PubMed     Text format    
    
    
    
58. PRINTZ C
    Active surveillance helps prostate cancer patients keep quality of life, findings show.
    Cancer. 2017;123:2997.
    PubMed     Text format    
    
    
    
59. MEDHANIE GA, Fedewa SA, Adissu H, DeSantis CE, et al
    Cancer incidence profile in sub-Saharan African-born blacks in the United States: Similarities and differences with US-born non-Hispanic blacks.
    Cancer. 2017;123:3116-3124.
    PubMed     Text format     Abstract available
    
    
    
60. JAGAI JS, Messer LC, Rappazzo KM, Gray CL, et al
    County-level cumulative environmental quality associated with cancer incidence.
    Cancer. 2017;123:2901-2908.
    PubMed     Text format     Abstract available
    
    
    
61. GORE JL, du Plessis M, Santiago-Jimenez M, Yousefi K, et al
    Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study.
    Cancer. 2017;123:2850-2859.
    PubMed     Text format     Abstract available
    
    
    July 2017
62. POLLACK CE, Armstrong KA, Mitra N, Chen X, et al
    A multidimensional view of racial differences in access to prostate cancer care.
    Cancer. 2017 Jul 20. doi: 10.1002/cncr.30894.
    PubMed     Text format     Abstract available
    
    
    
63. EBOT EM, Gerke T, Labbe DP, Sinnott JA, et al
    Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer.
    Cancer. 2017 Jul 12. doi: 10.1002/cncr.30831.
    PubMed     Text format     Abstract available
    
    
    
64. HURWITZ LM, Cullen J, Kim DJ, Elsamanoudi S, et al
    Longitudinal regret after treatment for low- and intermediate-risk prostate cancer.
    Cancer. 2017 Jul 5. doi: 10.1002/cncr.30841.
    PubMed     Text format     Abstract available
    
    
    
65. LEWIS DR, Chen HS, Cockburn MG, Wu XC, et al
    Early estimates of SEER cancer incidence, 2014.
    Cancer. 2017;123:2524-2534.
    PubMed     Text format     Abstract available
    
    
    June 2017
66. SCHULMAN AA, Howard LE, Tay KJ, Tsivian E, et al
    Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system.
    Cancer. 2017 Jun 29. doi: 10.1002/cncr.30844.
    PubMed     Text format     Abstract available
    
    
    
67. PILIE PG, Johnson AM, Hanson KL, Dayno ME, et al
    Germline genetic variants in men with prostate cancer and one or more additional cancers.
    Cancer. 2017 Jun 28. doi: 10.1002/cncr.30817.
    PubMed     Text format     Abstract available
    
    
    
68. POMERANTZ MM, Spisak S, Jia L, Cronin AM, et al
    The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.
    Cancer. 2017 Jun 13. doi: 10.1002/cncr.30808.
    PubMed     Text format     Abstract available
    
    
    
69. RIMAR KJ, Tran PT, Matulewicz RS, Hussain M, et al
    The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
    Cancer. 2017;123:1912-1924.
    PubMed     Text format     Abstract available
    
    
    May 2017
70. FRENDL DM, Olumi AF
    Understanding temporal trends in medical costs associated with progression to metastatic prostate cancer.
    Cancer. 2017 May 23. doi: 10.1002/cncr.30779.
    PubMed     Text format    
    
    
    
71. LI TT, Shore ND, Mehra M, Todd MB, et al
    Impact of subsequent metastases on costs and medical resource use for prostate cancer patients initially diagnosed with localized disease.
    Cancer. 2017 May 23. doi: 10.1002/cncr.30784.
    PubMed     Text format     Abstract available
    
    
    
72. VETTERLEIN MW, Loppenberg B, Karabon P, Dalela D, et al
    Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer.
    Cancer. 2017 May 4. doi: 10.1002/cncr.30744.
    PubMed     Text format     Abstract available
    
    
    April 2017
73. WALLNER LP, Jacobsen SJ
    Prostate cancer in black men: Is it time for personalized screening approaches?
    Cancer. 2017 Apr 24. doi: 10.1002/cncr.30685.
    PubMed     Text format    
    
    
    
74. TSODIKOV A, Gulati R, de Carvalho TM, Heijnsdijk EAM, et al
    Is prostate cancer different in black men? Answers from 3 natural history models.
    Cancer. 2017 Apr 24. doi: 10.1002/cncr.30687.
    PubMed     Text format     Abstract available
    
    
    
75. LAYNE TM, Weinstein SJ, Graubard BI, Ma X, et al
    Serum 25-hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men.
    Cancer. 2017 Apr 3. doi: 10.1002/cncr.30634.
    PubMed     Text format     Abstract available
    
    
    March 2017
76. HURWITZ MD, Harris J, Sartor O, Xiao Y, et al
    Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
    Cancer. 2017 Mar 21. doi: 10.1002/cncr.30620.
    PubMed     Text format     Abstract available
    
    
    February 2017
77. ADAMO MP, Boten JA, Coyle LM, Cronin KA, et al
    Validation of prostate-specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries.
    Cancer. 2017;123:697-703.
    PubMed     Text format     Abstract available
    
    
    
78. GOKCE MI, Wang X, Frost J, Roberson P, et al
    Informed decision making before prostate-specific antigen screening: Initial results using the American Cancer Society (ACS) Decision Aid (DA) among medically underserved men.
    Cancer. 2017;123:583-591.
    PubMed     Text format     Abstract available
    
    
    
79. WANG H, Hoda RS, Faquin W, Rossi ED, et al
    FNA biopsy of secondary nonlymphomatous malignancies in salivary glands: A multi-institutional study of 184 cases.
    Cancer. 2017;125:91-103.
    PubMed     Text format     Abstract available
    
    
    January 2017
80. COLLINS GS, Le Manach Y
    Nomograms need to be presented in full.
    Cancer. 2017;123:177-178.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: